The value of genomic sequencing in complex pediatric neurological disorders: a discrete choice experiment

[1]  J. Christodoulou,et al.  The personal utility and uptake of genomic sequencing in pediatric and adult conditions: eliciting societal preferences with three discrete choice experiments , 2020, Genetics in Medicine.

[2]  J. Braithwaite,et al.  Clinical genomic testing: what matters to key stakeholders? , 2020, European Journal of Human Genetics.

[3]  C. Patch,et al.  Parents’ motivations, concerns and understanding of genome sequencing: a qualitative interview study , 2020, European Journal of Human Genetics.

[4]  S. Rasmussen,et al.  Exome sequencing: value is in the eye of the beholder , 2019, Genetics in Medicine.

[5]  D. Veenstra,et al.  Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study , 2019, PharmacoEconomics.

[6]  K. Boycott,et al.  The value of diagnostic testing for parents of children with rare genetic diseases , 2019, Genetics in Medicine.

[7]  S. Scherer,et al.  Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders , 2019, Genetics in Medicine.

[8]  Alan R. Ellis,et al.  Discrete Choice Experiments in Health Economics: Past, Present and Future , 2018, PharmacoEconomics.

[9]  Deirdre Weymann,et al.  Valuation of Health and Nonhealth Outcomes from Next-Generation Sequencing: Approaches, Challenges, and Solutions. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  Kathryn A Phillips,et al.  Themed Section: Assesing the Value of Next-Generation Sequencing Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions , 2018 .

[11]  S. Kingsmore,et al.  Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases , 2018, npj Genomic Medicine.

[12]  Deirdre Weymann,et al.  Patient preferences for massively parallel sequencing genetic testing of colorectal cancer risk: a discrete choice experiment , 2018, European Journal of Human Genetics.

[13]  Peter Vickerman,et al.  How well do discrete choice experiments predict health choices? A systematic review and meta-analysis of external validity , 2018, The European Journal of Health Economics.

[14]  M. T. Nguyen,et al.  Diagnosis of rare diseases under focus: impacts for Canadian patients , 2017, Journal of Community Genetics.

[15]  Gert Jan van der Wilt,et al.  A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology , 2017, Genetics in Medicine.

[16]  J. Kohler,et al.  Personal utility in genomic testing: a systematic literature review , 2017, European Journal of Human Genetics.

[17]  Andrew T. Collins,et al.  On determining priors for the generation of efficient stated choice experimental designs , 2016 .

[18]  Y. Bombard,et al.  How do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experiment , 2016, BMJ Open.

[19]  A. Schuh,et al.  Patients’ Preferences for Genomic Diagnostic Testing in Chronic Lymphocytic Leukaemia: A Discrete Choice Experiment , 2016, The Patient - Patient-Centered Outcomes Research.

[20]  J. Rivière,et al.  Diagnostic odyssey in severe neurodevelopmental disorders: toward clinical whole‐exome sequencing as a first‐line diagnostic test , 2016, Clinical genetics.

[21]  John M. Rose,et al.  Applied Choice Analysis , 2015 .

[22]  E. Estrella,et al.  “Is it Going to Hurt?”: The Impact of the Diagnostic Odyssey on Children and Their Families , 2015, Journal of Genetic Counseling.

[23]  David Veenstra,et al.  Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experiment , 2015, Canadian Medical Association Journal.

[24]  Xuan Yuan,et al.  Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders , 2014, Science Translational Medicine.

[25]  Siddharth Srivastava,et al.  Clinical whole exome sequencing in child neurology practice , 2014, Annals of neurology.

[26]  David L Veenstra,et al.  The economics of genomic medicine: insights from the IOM Roundtable on Translating Genomic-Based Research for Health. , 2013, JAMA.

[27]  John M. Rose,et al.  Sample size requirements for stated choice experiments , 2013 .

[28]  Ray B. Jones,et al.  Living without a diagnosis: the parental experience. , 2010, Genetic testing and molecular biomarkers.

[29]  Carol A. Marra,et al.  Valuing the benefit of diagnostic testing for genetic causes of idiopathic developmental disability: willingness to pay from families of affected children , 2009, Clinical genetics.

[30]  K. Payne,et al.  Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis , 2008, Genetics in Medicine.

[31]  Julie Ratcliffe,et al.  Measuring and valuing health benefits for economic evaluation in adolescence: an assessment of the practicality and validity of the child health utility 9D in the Australian adolescent population. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[32]  Joanna Coast,et al.  Developing attributes and levels for discrete choice experiments using qualitative methods , 2007, Journal of health services research & policy.

[33]  Joel R. Evans,et al.  The value of online surveys , 2005, Internet Res..

[34]  David A. Hensher,et al.  A latent class model for discrete choice analysis: contrasts with mixed logit , 2003 .

[35]  K. Small,et al.  Applied Welfare Economics with Discrete Choice Models , 1979 .

[36]  Deborah Marshall,et al.  Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[37]  Peter Goos,et al.  Bayesian optimal designs for discrete choice experiments with partial profiles , 2011 .

[38]  Mandy Ryan,et al.  Using discrete choice experiments to value health and health care , 2008 .